China-based contract research organization Crystal Pharmatech has partnered with contract drug development company Particle Sciences to offer clients an optimal solution for developing low solubility pharmaceutical compounds.
Subscribe to our email newsletter
Under the partnership, Crystal Pharmatech combines its expertise with Particle Sciences advanced drug delivery solutions compounds to offer clients an optimal solution for developing low solubility pharmaceutical compounds.
Particle Sciences pharmaceutical development division vice president Robert Lee said, "Often times, a client will work with a CRO to find a path forward for API development, only to realize that the chosen path is unacceptable for formulation development and, as a result, the project goes over the allocated time and budget."
Headquartered in Suzhou, China, Crystal Pharmatech is a technology-driven CRO, which offers materials research service for active pharmaceutical ingredients and formulations used in drug discovery.